Publications | Lund University Publications

1 – 8 of 8

show: 10
|
sort: year (new to old)

News feed Embed this list Save this search Mark all Export

Cancel

Embed this list

copy and paste the html snippet below into your own page:

<iframe src="https://lup.lub.lu.se/search/publication?embed=1&q=author%3D%22Wist%2C+E%22+or+(documentType+any+%22bookEditor+conferenceEditor%22+and+editor%3D%22Wist%2C+E%22)&amp;hide_pagination=1&amp;hide_info=1&amp;hide_options=1"
  width="100%"
  height="400"
  allowtransparency="true"
  frameborder="0">
</iframe>

2007
Mark Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy
Wilking, N. ; Lidbrink, E. ; Wiklund, T. ; Erikstein, B. ; Lindman, H. ; Malmström, Per ^LU ; Kellokumpu-Lehtinen, P. ; Bengtsson, N. -O. ; Soederlund, G. and Anker, G. , et al. (2007) In Annals of Oncology 18(4). p.694-700
- Contribution to journal › Article
2002
Mark Tumour microvessel density as predictor of chemotherapy response in breast cancer patients
Tynninen, O ; Sjostrom, J ; von Boguslawski, K ; Bengtsson, NO ; Heikkila, R ; Malmström, Per ^LU ; Ostenstad, B ; Wist, E ; Valvere, V and Saksela, E , et al. (2002) In British Journal of Cancer 86(12). p.1905-1908
- Contribution to journal › Article
Mark The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer
Sjostrom, J ; Blomqvist, C ; von Boguslawski, K ; Bengtsson, NO ; Mjaaland, I ; Malmström, Per ^LU ; Ostenstadt, B ; Wist, E ; Valvere, V and Takayama, S , et al. (2002) In Clinical Cancer Research 8(3). p.811-816
- Contribution to journal › Article
Mark C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer
Sjostrom, J ; Collan, J ; von Boguslawski, K ; Franssila, K ; Bengtsson, NO ; Mjaaland, I ; Malmström, Per ^LU ; Ostenstad, B ; Wist, E and Valvere, V , et al. (2002) In European Journal of Cancer 38(4). p.535-542
- Contribution to journal › Article
Mark Physical performance, toxicity, and quality of life as assessed by the physician and the patient
Luoma, ML ; Hakamies-Blomqvist, L ; Sjostrom, J ; Mouridsen, H ; Pluzanska, A ; Malmström, Per ^LU ; Bengtsson, NO ; Hultborn, R ; Ostenstaad, B and Mjaaland, I , et al. (2002) In Acta Oncologica 41(1). p.44-49
- Contribution to journal › Article
2000
Mark Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer
Sjöström, J ; Blomqvist, C ; Heikkilä, P ; Boguslawski, K V ; Räisänen-Sokolowski, A ; Bengtsson, N O ; Mjaaland, I ; Malmström, Per ^LU ; Ostenstadt, B and Bergh, J , et al. (2000) In Clinical Cancer Research 6(8). p.3103-3110
- Contribution to journal › Article
Mark Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer : a randomised trial
Bergh, J ; Wiklund, T ; Erikstein, B ; Lidbrink, E ; Lindman, H ; Malmström, Per ^LU ; Kellokumpu-Lehtinen, P ; Bengtsson, N O ; Söderlund, G and Anker, G , et al. (2000) In The Lancet 356(9239). p.1384-1391
- Contribution to journal › Article
1998
Mark Dacarbazine-vindesine versus dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A randomised phase III trial
Jungnelius, U ; Ringborg, U ; Aamdal, S ; Mattsson, J ; Stierner, U ; Ingvar, C ^LU ; Malmström, P ^LU ; Andersson, R ; Karlsson, M and Willman, K , et al. (1998) In European Journal of Cancer 34(9). p.1368-1374
- Contribution to journal › Article